Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry

Agnieszka Kapløn-Cießlicka 1,2, Monika Gawalko 1,2,3,4,* Monika Budnik 1,2, Beata Uziębło-Życzkowska 5, Paweł Kresziński 1,8, Katarzyna Starzyk 6, Iwona Gorczyca-Głowacka 6, Ludmila Danilowicz-Szymanowicz 7, Damian Kaufmann 7, Maciej Wójcik 1,8, Robert Błaszczyk 8, Jarosław Hiczkiewicz 9,10, Katarzyna Łojewska 10, Katarzyna Mizia-Stec 1,11, Maciej T Wybraniec 1,11, Katarzyna Kosmalska 12, Marcin Fijałkowski 1,13, Anna Szymańska 1,14, Mirosław Dłużniewski 14, Maciej Haberka 1,15, Michał Kucio 15, Błażej Michałski 1,16, Karolina Kuczyńska 1,16, Anna Tomaszuk-Kazberuk 1,17, Katarzyna Wilk-Ślędziewska 17, Renata Wachnicka-Truty 18, Marek Koziński 1,18, Paweł Burchardi 1,19, Piotr Scisło 2, Radosław Piątkowski 1,2, Janusz Kochanowski 2, Grzegorz Opolski 2 and Macin Grabowski 1,2

Abstract: Background: Atrial fibrillation (AF) and flutter (AFl) increase the risk of thromboembolism. The aim of the study was to assess the prevalence of left atrial thrombus (LAT) in AF/AFl in relation to oral anticoagulation (OAC). Methods: LATTEE (NCT03591627) was a multicenter, prospective, observational study enrolling consecutive patients with AF/AFl referred for transesophageal echocardiography before cardioversion or ablation. Results: Of 3109 patients enrolled, 88% were on chronic, oral anticoagulation (OAC).
1.5% on transient OAC and 10% without OAC. Of patients on chronic OAC, 39% received rivaroxaban, 30% dabigatran, 14% apixaban and 18% vitamin K antagonists (VKA). Patients on apixaban were oldest, had the worst renal function and were highest in both bleeding and thromboembolic risk, and more often received reduced doses. Prevalence of LAT was 8.0% (7.3% on chronic OAC vs. 15% without OAC; p < 0.01). In patients on VKA, prevalence of LAT was doubled compared to patients on non-VKA-OACs (NOACs) (13% vs. 6.0%; p < 0.01), even after propensity score weighting (13% vs. 7.5%; p < 0.01). Prevalence of LAT in patients on apixaban was higher (9.8%) than in those on rivaroxaban (5.7%) and dabigatran (4.7%; p < 0.01 for both comparisons), however, not after propensity score weighting. Conclusions: The prevalence of LAT in AF is non-negligible even on chronic OAC. The risk of LAT seems higher on VKA compared to NOAC, and similar between different NOACs.

Keywords: thromboembolic risk; apixaban; dabigatran; rivaroxaban; transesophageal echocardiography

1. Introduction
Atrial fibrillation (AF) and atrial flutter (AFl) increase the risk of thromboembolic events [1–3]. Current guidelines recommend initiation of oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or, preferably, non-VKA-OACs (NOACs) in men and women with a CHA2DS2VASc score of ≥2 and ≥3, respectively [4]. Effective OAC is also recommended three weeks before elective AF cardioversion or catheter ablation with pre-procedural transesophageal echocardiography (TEE) as an alternative [4]. However, TEE before AF/AFl cardioversion or ablation is often performed even in anticoagulated patients, given that, in clinical practice, “effective” OAC may be difficult to achieve and/or verify.

The aim of the study was to assess the prevalence of LA thrombus in real-world AF/AFl patients referred for TEE before electrical cardioversion or catheter ablation in relation to the presence and the type of OAC.

2. Materials and Methods
2.1. Patient and Public Involvement
The Left Atrial Thrombus on Transesophageal Echocardiography (LATTEE) registry (NCT03591627) was a prospective, observational study enrolling consecutive patients with AF or AFl in whom TEE was performed before direct current cardioversion or catheter ablation, hospitalized in 13 cardiology departments (11 academic centers and two territorial departments) in Poland. Details on the study rationale and design have been reported elsewhere [5]. The patient recruitment process started in November 2018 in the coordinating centre and lasted 12 months since the beginning of the study in each participating centre or longer, i.e., until the inclusion of at least 200 patients at each participating centre (with the last patient enrolled in May 2020). Patients in whom TEE was performed several times during the study period were entered in the database under the same number.

The diagnosis of AF/AFl was made by attending physicians in accordance with the current guidelines [6]. Referral for TEE and performance of other diagnostic tests depended on the routine practice of a particular center and on the decision of an attending physician. Ten centers with electrophysiology teams performed TEE before catheter ablation in all AF/AFl patients and three centers in those questionable about adherence to OAC. Regarding non-emergency electrical cardioversion for AF/AFl, four centers performed TEE routinely in all patients, and nine centers performed TEE only in patients not pre-treated with OAC or in case of uncertainty of patients’ adherence to NOAC or, in patients on VKA, if the international normalized ratio (INR) was in non-therapeutic ranges.

The study was approved by the Ethics Committee of Medical University of Warsaw (AKBE/113/2018). Data were entered into the registry database anonymously. No additional tests or interventions, apart from those planned by the attending physicians, were
performed. Thus, the ethics committee waived the requirement of obtaining informed consent from the patients.

2.2. Data Collection

Data was gathered prospectively and included demographics, medical history, current pharmacotherapy, results of routine laboratory tests (on hospital admission), and TEE results in all patients. Chronic OAC was defined as OAC treatment for at least three weeks before the procedure. Transient OAC was defined as OAC prescribed for less than three weeks, usually a few days before the procedure. Glomerular filtration rate (GFR) was estimated using the Cockcroft-Gault formula: ([140-age] × weight in [kilograms/serum creatinine] in [mg/d] × 72) × 0.85 (if female). The primary outcome measure was the prevalence of LA thrombus on TEE. Apart from LA thrombus, data on spontaneous echo contrast (SEC), including dense SEC (grades 3–4 in the scoring system [7]) were also gathered. LA appendage emptying velocity was measured 1 cm below the orifice of the appendage. All TEE studies were performed by certified echocardiographers.

2.3. Statistical Analysis

All continuous variables were tested for normality with the Kolmogorov-Smirnov test. Nonparametric variables were expressed as median and interquartile range [IQR], and categorical variables as counts (n) with percentages (%). Fisher’s exact test (two group comparisons) or Chi-square tests (three group comparisons) were used to compare categorical variables. Differences in continuous parameters were compared using a Mann-Whitney U test (two group comparisons) and Kruskal-Wallis test (three groups comparisons) in case of nonparametric variables and unpaired t-test (two group comparison) or ANOVA (three groups comparison) in the case of parametric variables. To compare the risk of LA thrombus in patients on different OAC regimens, univariate (unadjusted) and multivariable (adjusted) logistic regression analyses were performed. In multivariable analyses, the effect of OAC strategy on the risk of LA thrombus was adjusted for age, sex, the presence of heart failure, hypertension, diabetes, vascular disease, and previous ischemic stroke, transient ischemic attack (TIA) or systemic embolism (variables included in the CHA\textsubscript{2}DS\textsubscript{2}-VASc score), and, additionally, for AF/AFl type (non-paroxysmal vs. paroxysmal), GFR and concomitant antiplatelet treatment. While comparing the prevalence of LA thrombus between different OAC strategies, to adjust for potential confounding due to baseline imbalances in study covariates while preserving sample size, we used propensity score weighting. With this method, the propensity score was used to generate patient-specific stabilized weights that control for covariate imbalances. Covariates used for propensity score weighting included age ≥ 65 years, sex, heart failure, hypertension, vascular disease, diabetes, ischemic stroke/TIA/systemic embolism (variables included in the CHA\textsubscript{2}DS\textsubscript{2}-VASc score), as well as GFR < 50 mL/min and LA appendage emptying velocity. Covariate balance between the weighted cohorts was assessed using standardized mean differences. A standardized difference of 0.05 or more indicates a negligible difference between groups. The distributions of propensity scores and stabilized weights were inspected for outliers. A two-sided p value of 0.05 was considered statistically significant. For database management and statistical analysis, we used SAS 14.1 (SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Population

Overall, 3109 patients were enrolled in the LATTEE registry: 2689 (86%) in academic and 420 (14%) in territorial centers. Median age was 67 (59–73) years, 37% were women, 85% had AF, 12% AFl, and 3.1% both AF and AFl. Median CHA\textsubscript{2}DS\textsubscript{2}-VASc score was 3 (2–4). In 52%, TEE was performed before cardioversion. Detailed characteristics of the LATTEE population are presented in Table S1 (Supplementary Material online).
3.2. Oral Anticoagulation

Data on OAC therapy (none, transient or chronic) was available for 3107 (99.9%) patients, with 88% on chronic OAC, 1.5% on transient OAC, and 10% without OAC (Figure 1A). Of patients on chronic OAC, 18% received VKA and 82% NOAC (17% of the latter received reduced doses; Figure 1B). Proportions of patients on chronic OAC were similar regardless of class of recommendation (89% in patients with class I indications to chronic OAC, 88% with class IIa indications and 85% with no indications; Figure 1C). Compared to patients on chronic OAC, those with no previous OAC were more often referred for cardioversion and less often for ablation. They had similar median age and CHA$_2$DS$_2$-VASc score, but they more often had a history of bleeding, had slightly lower GFR and were more often treated with antiplatelets. They received periprocedural heparin significantly more often than those on chronic OAC (35% vs. 4%; Table S1).
Figure 1. Oral anticoagulation in patients with atrial fibrillation/flutter undergoing transesophageal echocardiography before cardioversion or ablation. (A): Presence and type of oral anticoagulation (n = 3107). (B): Dosing of non-vitamin K oral anticoagulants (NOAC) (n = 2259). (C): Oral anticoagulation in relation to indications to chronic anticoagulation (n = 3087). Legend: No indications to chronic anticoagulation: CHA2DS2-VASc 0 (if male) and 1 (if female). Class I indications to chronic anticoagulation: CHA2DS2-VASc 1 (if male) and 2 (if female). Class IIa indications to chronic anticoagulation: CHA2DS2-VASc ≥ 2 (if male) and ≥3 (if female) or moderate-severe mitral stenosis or mechanical valve prosthesis; Reduced doses for rivaroxaban, dabigatran and apixaban were 15 mg o.d., 110 mg b.i.d. and 2.5 mg b.i.d., respectively. Only one patient in the rivaroxaban group received a reduced dose of 10 mg o.d. Only p-values of 0.05 or lower were shown for group comparisons; Abbreviations: NOAC, non-vitamin K oral anticoagulant; OAC, oral anticoagulation; VKA, vitamin K antagonist.

3.3. Left Atrial Thrombus

Overall, the prevalence of LA thrombus on TEE was 8.0% and was lowest in patients on chronic OAC (7.3%) and highest in those with no OAC (15%; p < 0.01; Figure 2A). 96% of LA thrombi were localized in its appendage. The prevalence of LA thrombus in patients with both AF and AFL, only AF and only AFL episodes, was 4.2%, 8.2% and 8.2% (p = 0.37), respectively. Compared to patients with no thrombus, those with LA thrombus were older, more often had non-paroxysmal AF, had more comorbidities with higher median CHA2DS2-VASc score (4 (3–5) vs. 3 (2–4); p < 0.01), were less often treated with OAC, but were treated with antiplatelets more often and more often received periprocedural heparin (Table S2; Supplementary Material online). Still, most LA thrombi occurred in patients on chronic OAC (80%) and with class I indications to OAC (93%) (Figure S1; Supplementary Material online). The prevalence of LA thrombus in anticoagulated patients with class I indications to OAC was 8.6%, with class IIa indications 2.4%, and with no indications 0.9% (p < 0.01; Figure S2; Supplementary Material online).

Figure 2. Cont.
3.4. VKA vs. NOAC

In patients on VKA, the prevalence of LA thrombus was twice as high as in patients on NOAC (13% vs. 6.0%; \( p < 0.01 \); Figure 2B). Compared to patients on NOAC, those on VKA were older, more often had non-paroxysmal AF and, unsurprisingly, mechanical valve prostheses and had more comorbidities with slightly higher CHA\(_2\)DS\(_2\)-VASc score (with a median score of 3 for both VKA and NOAC), and with somewhat worse renal function (Table 1). However, even after multiple adjustments for potential confounders, the risk of LA thrombus remained twice as high with VKA as with NOAC (Figure 3). In propensity score weighting, the prevalence of LA thrombus in 491 patients on VKA was 13% and in 491 matched patients on NOAC it was 7.5% \( (p < 0.01) \); Table S3).
Table 1. Baseline characteristics of patients on chronic oral anticoagulation in relation to type of anticoagulation.

| Variable                  | VKA (n = 491) | NOAC (n = 2262) | p 1   | NOAC (n = 2262) | p 2   |
|---------------------------|---------------|-----------------|-------|-----------------|-------|
|                           |               | Rivaroxaban     |       | Dabigatran      |       |
|                           |               | (n = 1060)      |       | (n = 814)       |       |
|                           |               | Apixaban        |       |                 |       |
|                           |               | (n = 388)       |       |                 |       |
| Demographics              |               |                 |       |                 |       |
| Age (years)               | 68 [62–74]    | 66 [59–73]      | <0.01 | 66 [58–73]      | <0.01 |
|                           | n = 490       | n = 2259        |       | n = 1059        |       |
|                           |               |                 |       | 65 [58–72]      | <0.01 |
|                           |               |                 |       | n = 812         |       |
|                           |               |                 |       | 71 [63–77]      | <0.01 |
|                           |               |                 |       | n = 388         |       |
| Age ≥ 75 years            | 108/490 (22%) | 471/2259 (21%)  | 0.58  | 200/1059 (19%)  | <0.01 |
|                           |               |                 |       | 146/812 (18%)   |       |
|                           |               |                 |       | 125/388 (32%)   |       |
| Female sex                | 196/491 (40%) | 826/2262 (37%)  | 0.16  | 380/1060 (36%)  | 0.02  |
|                           |               |                 |       | 281/814 (35%)   |       |
|                           |               |                 |       | 165/388 (43%)   |       |
| BMI (kg/m²)               | 29 [26–33]    | 29 [26–33]      | 0.55  | 29 [26–33]      | 0.26  |
|                           | n = 463       | n = 2107        |       | n = 983         |       |
| Indications for TEE       |               |                 |       |                 |       |
| Direct current cardioversion for AF/AFl | 282/475 (59%)  | 1055/2236 (47%) | <0.01 | 501/1052 (48%)  | <0.01 |
| AF/AFl ablation           | 193/475 (41%) | 1181/2236 (53%) | <0.01 | 551/1052 (52%)  | <0.01 |
| AF/AFl type               |               |                 |       |                 |       |
| AF                        | 428/491 (87%) | 2025/2262 (90%) | 0.13  | 956/1060 (90%)  | 0.02  |
|                           |               |                 |       | 737/814 (91%)   |       |
|                           |               |                 |       | 332/388 (86%)   |       |
| AFl                       | 80/491 (16%)  | 309/2262 (14%)  | 0.13  | 137/1060 (13%)  | 0.02  |
|                           |               |                 |       | 102/814 (13%)   |       |
|                           |               |                 |       | 70/388 (18%)    |       |
| AF/AFl paroxysmal         | 158/487 (32%) | 969/2259 (43%)  | <0.01 | 458/1059 (43%)  | <0.01 |
| AF/AFl persistent         | 262/487 (54%) | 1107/2259 (49%) | 0.06  | 528/1058 (50%)  | <0.01 |
| AF/AFl long-standing persistent | 67/487 (14%) | 183/2259 (8.1%) | <0.01 | 73/1059 (6.9%)  | <0.01 |
| Comorbidities             |               |                 |       |                 |       |
| Hypertension              | 385/490 (79%) | 1736/2261 (77%) | 0.41  | 811/1060 (77%)  | 0.41  |
|                           |               |                 |       | 618/814 (76%)   |       |
|                           |               |                 |       | 307/387 (79%)   |       |
| Heart failure             | 254/491 (52%) | 902/2253 (40%)  | <0.01 | 410/1057 (39%)  | <0.01 |
| Mechanical valve prosthesis | 68/491 (14%) | 3/2258 (0.1%) | <0.01 | 1/1060 (0.1%) | 0.75 |
| Biological valve prosthesis including TAVI | 24/491 (4.9%) | 24/2258 (1.1%) | <0.01 | 8/1060 (0.8%) | 0.39 |
| Vascular disease          | 193/490 (39%) | 755/2261 (33%)  | 0.01  | 333/1060 (31%)  | <0.01 |
| Previous stroke           | 40/490 (8.2%) | 171/2261 (7.6%) | 0.64  | 69/1060 (6.5%)  | 0.07  |
| Ischemic stroke/TIA/systemic embolism | 56/488 (11%) | 229/2259 (10%) | 0.37  | 91/1060 (8.6%)  | 0.03  |
| Previous bleeding         | 17/490 (3.5%) | 82/2261 (3.6%)  | 1.00  | 29/1060 (2.7%)  | <0.01 |
| Diabetes mellitus         | 141/490 (29%) | 538/2261 (24%)  | 0.02  | 236/1060 (22%)  | 0.08  |
| GFR (mL/min)              | 80 [60–100]   | 82 [64–103]     | 0.049 | 84 [67–106]     | <0.01 |
|                           | n = 439       | n = 2031        |       | n = 946         |       |
|                           |               |                 |       | 85 [66–105]     | <0.01 |
|                           |               |                 |       | n = 734         |       |
| GFR < 50 mL/min           | 65/439 (15%)  | 200/2031 (9.9%) | <0.01 | 76/946 (8.0%)   | <0.01 |
| COPD                      | 31/490 (6.3%) | 105/2261 (4.6%) | 0.13  | 37/1060 (3.5%)  | 0.04  |
| Anemia ³                  | 102/472 (22%) | 312/2189 (14%)  | <0.01 | 123/1028 (12%)  | <0.01 |

³ Anemia defined as a hemoglobin concentration of less than 130 g/L in men and less than 115 g/L in women.
Table 1. Cont.

| Variable | VKA (n = 491) | NOAC (n = 2262) | p 1 | NOAC (n = 2262) | p 2 |
|----------|---------------|----------------|-----|----------------|-----|
|          |               |                |     | Rivaroxaban (n = 1060) |     |
|          |               |                |     | Dabigatran (n = 814) |     |
|          |               |                |     | Apixaban (n = 388) |     |
|          |               |                |     |                   |     |
| Thromboembolic risk and indications to chronic OAC | | | | | |
| CHA2DS2-VASc score | 3 [2–5] n = 487 | 3 [2–4] n = 2246 | <0.01 | 3 [2–4] n = 1056 | <0.01 |
| Class I indications to OAC a | 414/488 (85%) | 1632/2246 (73%) | <0.01 | 767/1056 (73%) | 315/385 (82%) |
| -moderate/severe MS or mechanical valve prosthesis | 77/488 (16%) | 10/2246 (0.4%) | <0.01 | 5/1056 (0.5%) | 3/385 (0.8%) |
| Class IIa indications b | 53/488 (11%) | 408/2246 (18%) | <0.01 | 185/1056 (18%) | 48/385 (12%) |
| No indications to chronic OAC c | 21/488 (4.3%) | 206/2246 (9.2%) | <0.01 | 104/1056(9.9%) | 22/385 (5.7%) |

Data on INR during hospitalization | 473/491 (96%) | | | |

INR 2–3 at hospital admission | 197/473 (42%) | | | |

Data on INR before hospitalization | 332/491 (68%) | | | |

INR 2–3 before hospitalization | 178/332 (46%) | | | |

Antithrombotic therapy | | | | |
| Heparin (periprocedural): | 32/489 (6.5%) | 77/2255 (3.4%) | <0.01 | 38/1056 (3.6%) | 0.89 |
| -heparin ≥ 2 days | 14/489 (2.9%) | 9/2253 (0.4%) | <0.01 | 4/1056 (0.4%) | 2/386 (0.5%) |
| Antplatelets | 69/491 (14%) | 169/2246 (7.5%) | <0.01 | 66/1056(6.2%) | 43/388 (11%) |

Transesophageal echocardiography | | | | |
| Left atrial appendage emptying velocity (cm/s) | 30 [20–44] n = 419 | 40 [28–55] n = 1917 | <0.01 | 40 [28–55] n = 897 | <0.01 |
| SEC | 165/485 (34%) | 523/2236 (23%) | <0.01 | 250/1048 (24%) | 102/383 (27%) |
| Left atrial thrombus | 64/491 (13%) | 136/2262 (6.0%) | <0.01 | 60/1060 (5.7%) | 38/388 (9.8%) |

Legend: a p value for the difference between patients on VKA vs. no NOAC; b p value for difference between rivaroxaban, dabigatran and apixaban; c hemoglobin < 12 g/dL for female < 13 g/dL for male; d CHA2DS2-VASc score ≥ 2 for men and ≥3 for women or moderate-severe MS or mechanical valve prosthesis; e CHA2DS2-VASc score 0 for men and 1 for women. Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; BMI, body mass index; COP, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; OAC, oral anticoagulation; NOAC, non-vitamin K oral anticoagulant; SEC, spontaneous echo contrast; VKA, vitamin K antagonist.
Figure 3. Risk of left atrial thrombus in patients with atrial fibrillation/flutter in relation to oral anticoagulation. (A): Unadjusted. (B): Adjusted for age, sex, heart failure, hypertension, diabetes, vascular disease, and previous ischemic stroke/TIA/systemic embolism. (C): Adjusted for age, sex, heart failure, hypertension, diabetes, vascular disease, previous ischemic stroke/TIA/systemic embolism, atrial fibrillation/flutter type (non-paroxysmal vs. paroxysmal), glomerular filtration rate, and antiplatelets. (D): In patients on standard doses of NOACs. Adjusted for age, sex, heart failure, hypertension, diabetes, vascular disease, previous ischemic stroke/TIA/systemic embolism, atrial fibrillation/flutter type (non-paroxysmal vs. paroxysmal), glomerular ejection fraction, and antiplatelets. Abbreviations: CI, coincidence interval; NOAC, non-vitamin K oral anticoagulant; OAC, oral anticoagulation; OR, odds ratio; VKA, vitamin K antagonist.

3.5. Apixaban vs. Rivaroxaban vs. Dabigatran

Of patients on chronic OAC, 39% received rivaroxaban, 30% dabigatran and 14% apixaban (Figure 1A). Patients treated with apixaban more often received reduced doses (29%) compared to patients on rivaroxaban (14%) and dabigatran (17%; p < 0.01 for both comparisons;
Figure 1B). Patients on apixaban were older, more often had non-paroxysmal AF, had more comorbidities with higher median CHA₂DS₂-VASc score (4 [2–5] for apixaban vs. 3 [2–4] for rivaroxaban and 3 [1–4] for dabigatran; p < 0.01), had lower GFR, and more often a history of bleeding and anemia, and were more often treated with antiplatelets compared to patients on other NOACs (Table 1).

The prevalence of LA thrombus in patients on apixaban was twice as high (9.8%) as in those on rivaroxaban (5.7%) and dabigatran (4.7%; p < 0.01 for both comparisons; Figure 2B) and this difference remained in patients on standard NOAC doses (8.4% for apixaban vs. 4.3% for rivaroxaban and 4.0% for dabigatran; Figure 2C). Thus, the unadjusted risk of LA thrombus for apixaban was doubled compared to other NOAC (Figure 3A). However, after multiple adjustments for potential confounders (variables included in the CHA₂DS₂-VASc score, AF type, renal function [GFR] and antiplatelet treatment), there was no difference in the risk of LA thrombus between apixaban and other NOACs (both in all patients on NOAC and in those on standard NOAC doses; Figure 3C,D). In propensity score weighting, the prevalence of LA thrombus in patients treated with standard doses of dabigatran, rivaroxaban and apixaban was comparable (Table S3).

4. Discussion

The major findings of our study are as follows. First, in a real-world population of AF/AFl patients referred for TEE before cardioversion or ablation, the prevalence of LA thrombus was 7.3% despite chronic OAC. Second, the risk of LA thrombus seems higher on VKA compared to NOAC. Third, apixaban is more often prescribed in patients with higher bleeding risk and therefore also with higher thromboembolic risk, which may account for the higher prevalence of LA thrombus in apixaban-treated patients. However, after adjusting for clinical characteristics, the risk of LA thrombus for apixaban seems similar to that for rivaroxaban and dabigatran.

Similar to our study, in a recent meta-analysis of observational studies, the prevalence of LA thrombus in 9772 anticoagulated patients undergoing TEE before cardioversion or catheter ablation was 6.7%, with higher prevalence in patients on VKA (12% on VKA vs. 4.7% on NOAC) [8]. In meta-analyses of randomized controlled trials compared to VKA, NOACs were shown to reduce all-cause mortality, as well as the risk of stroke or systemic embolism; the latter driven mainly by a ~50% reduction in hemorrhagic stroke [9]. In terms of prevention of ischemic stroke, NOACs have demonstrated similar efficacy to VKA, with only a trend towards benefit with NOACs [10]. Lower relative efficacy of VKA in observational studies reporting on the prevalence of LA thrombus on TEE [8,11] could be explained by lower time in therapeutic range (TTR) in real-world patients [12] compared to TTR achieved in patients enrolled in clinical trials [13], and could imply even more benefit with NOACs compared to VKA in real-world AF population. Still, not every LA thrombus results in ischemic stroke and, thus, the higher prevalence of LA thrombus under VKA treatment might not necessarily translate into a higher risk of thromboembolic events.

All NOACs seem to provide comparable protection from thromboembolic events, while apixaban consistently demonstrated lower bleeding risk compared to rivaroxaban and dabigatran [14]. Even at the standard dose, apixaban seems to convey the lowest risk of major bleeding [15]. Of all NOACs, apixaban is eliminated by the kidney to the least extent, therefore, contrary to other NOACs, it can be used at a standard dose in patients with GFR between 30 and 49 mL/min, unless other indications to dose reduction are present [16]. Although neither the 2020 guidelines of the European Society of Cardiology [4] nor the 2021 European Heart Rhythm Association practical guide on the use of NOACs [16] provide clear recommendations on the choice of NOAC in specific clinical situations, in our real-life AF/AFl population, we observed a preference for apixaban in patients with the highest bleeding risk and the worst renal function (and a preference for rivaroxaban and dabigatran in those with the lowest bleeding risk, with VKA prescribed in the “intermediate” group): patients on apixaban were the oldest (median age: 71 years vs. 68 years on VKA vs. ~66 years on rivaroxaban and dabigatran), more often had a history
of previous bleeding (7.0% vs. 3.5% on VKA and ~3% on rivaroxaban and dabigatran) or anemia (19% vs. 22% on VKA vs. 12% on rivaroxaban and 15% on dabigatran) and more often had GFR < 50 mL/min (18% vs. 15% on VKA vs. ~8% on rivaroxaban and dabigatran). At the same time, patients on apixaban had the highest thromboembolic risk determined by both the highest median CHA2DS2-VASc score (4 vs. 3 on VKA, rivaroxaban and dabigatran and the worst renal function [17,18]. This, together with more frequent prescription of reduced doses, could account for the higher prevalence of LA thrombus in apixaban-treated patients compared to rivaroxaban- and dabigatran-treated patients. Importantly, both in multivariable logistic regression and propensity score weighting, the risk of LA thrombus for apixaban was comparable to other NOACs. On the other hand, for VKA, the risk of LA thrombus remained significantly higher compared to NOAC even after multiple adjustments and in propensity score weighting.

Current guidelines recommend TEE before AF cardioversion or catheter ablation as an alternative to a 3-week course of OAC [4]. In our study, the prevalence of LA thrombus on chronic OAC was 8.6% in patients with class I indications to OAC and over 3 times lower (2.4%) in those with class IIa indications. In patients with class I indications, the prevalence of LA thrombus was high both on VKA (13%) and on NOAC (7.6%), whereas in those with class IIa indications it was still high on VKA (11%), but much lower on NOAC (1.2%, \( p < 0.01 \)). Thus, it may be suggested that patients with high thromboembolic risk (class I indications to OAC) should not be exempted from TEE before cardioversion or catheter ablation even after three weeks of OAC treatment [19]. In patients with class IIa indications to OAC, TEE before cardioversion might be reasonable in patients treated with VKA if no evidence for effective TTR is available. Patients with no indications to OAC developed LA thrombus only occasionally (three patients, including two on chronic OAC).

Limitations

Our study was an observational one, and therefore results regarding efficacy of different OAC regimens should be viewed with some care. Nevertheless, propensity score weighting and multivariable logistic regression, adjusted for potential confounders, brought similar results with respect to the efficacy of VKA vs. NOAC and of different NOACs. The registry-based character of our study has its limitations, but also advantages, providing real-world estimates of the factual prevalence of LA thrombus during OAC treatment. Nine participating centers did not perform TEE routinely in all patients referred for cardioversion, only in those with doubts regarding adherence to NOAC or effectiveness of OAC, which might have led to some selection bias. Furthermore, most (86%) patients were enrolled in academic centers, which also might have led to some selection bias. Data on the indications to electrical cardioversion (urgent vs. elective cardioversion, first vs. recurrent episode of AF) were not collected in the registry. Next, diagnostic tests were performed at the discretion of attending physicians, and thus, some data are missing for some patients. Therefore, in tables, we have given the number of patients for whom a given parameter was available. Data on INR before index hospitalization were missing in one third of VKA-treated patients, and assessment of TTR was not possible. On the other hand, the study reflected real-world patients on VKA, who sometimes fail to adequately control INR. Finally, the primary endpoint of our study was the presence of LA thrombus on TEE, and not ischemic stroke. Not all ischemic strokes in AF result from LA thrombi, and not all LA thrombi lead to ischemic stroke. However, thrombus formation in LA is considered the primary mechanism responsible for thromboembolic events in patients with AF; thus, the design of our study seems appropriate to address thromboembolic risk in AF/AFl [1–3].

5. Conclusions

Prevalence of LA thrombus in AF is non-negligible even on chronic OAC, therefore TEE should be considered, if feasible, before cardioversion/ablation in all patients with high thromboembolic risk (class I indications to OAC) irrespective of OAC treatment. In
real-world AF/AFl population, the risk of LA thrombus seems higher on VKA compared to NOAC, and similar between different NOACs.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11102705/s1. Figure S1: Atrial fibrillation/flutter patients with left atrial thrombus on transesophageal echocardiography. Figure S2: Prevalence of left atrial thrombus in patients on chronic oral anticoagulation (OAC) in relation to indications to OAC. Table S1: Baseline characteristics of patients with atrial fibrillation/atrial flutter undergoing transesophageal echocardiography before cardioversion or ablation. Table S2: Baseline characteristics of all hospitalized atrial fibrillation patients depending on presence of left atrial thrombus (n = 3109). Table S3: Comparison of chronic OAC groups after propensity score weighting.

**Author Contributions:** Conceptualization, A.K.-C., M.G. (Monika Gawalko), M.B.; methodology, A.K.-C., M.G. (Monika Gawalko); validation, A.K.-C., M.G. (Monika Gawalko); formal analysis, A.K.-C., M.G. (Monika Gawalko); investigation, A.K.-C., M.G. (Monika Gawalko), M.B., B.U.-Ż., P.K., K.S., I.G.-G., L.D.-S., D.K., M.W., R.B., J.H., K.L., K.M.-S., M.T.W., K.K. (Katarzyna Kosmalska), M.F., A.S., M.D., M.H., M.K. (Michal Kuczyński), B.M., K.K. (Karolina Kupczyńska), A.T.-K., K.W.-Ś., R.W.-T, M.K. (Marek Kozirski), P.B., P.S., J.K., R.P., G.O., M.G. (Marcin Grabowski); data curation, A.K.-C., M.G. (Monika Gawalko), M.B., B.U.-Ż., P.K., K.S., I.G.-G., L.D.-S., D.K., M.W., R.B., J.H., K.L., K.M.-S., M.T.W., K.K. (Katarzyna Kosmalska), M.F., A.S., M.D., M.H., M.K. (Michal Kuczyński), B.M., K.K. (Karolina Kupczyńska), A.T.-K., K.W.-Ś., R.W.-T, M.K. (Marek Kozirski), P.B., P.S., J.K., R.P., G.O., M.G. (Marcin Grabowski); writing-original draft preparation, A.K.-C. and M.G. (Monika Gawalko); writing-review and editing, A.K.-C., M.G. (Monika Gawalko), M.B., B.U.-Ż., P.K., K.S., I.G.-G., L.D.-S., D.K., M.W., R.B., J.H., K.L., K.M.-S., M.T.W., K.K. (Katarzyna Kosmalska), M.F., A.S., M.D., M.H., M.K. (Michal Kuczyński), B.M., K.K. (Karolina Kupczyńska), A.T.-K., K.W.-Ś., R.W.-T, M.K. (Marek Kozirski), P.B., P.S., J.K., R.P., G.O., M.G. (Marcin Grabowski); supervision, A.K.-C.; project administration, A.K.-C., M.G. (Monika Gawalko); funding acquisition—non-applicable. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Medical University of Warsaw (AKBE/113/2018).

**Informed Consent Statement:** Patient consent was waived due to the fact no additional tests or interventions, apart from those planned by the attending physicians, were performed in patients.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The LATTEE Registry was initiated on the Scientific Platform of the “Club 30” of the Polish Cardiac Society. The authors thank Jan Budzianowski, Sebastian Liedtke, Konrad Piechko, Magdalena Mizia-Szubryt, Marek Szołkiewicz, Elżbieta Wabich, Dagmara Wojtowicz for their assistance in data collection and Jaroslaw D Kasprzak for content supervision.

**Conflicts of Interest:** M.G. (Monika Gawalko), M.B., B.U.-Ż., P.K., K.S., D.K., M.W., R.B., J.H., K.L., K.K. (Katarzyna Kosmalska), M.F., A.S., M.D., M.H., M.K. (Michal Kuczyński), B.M., K.K. (Karolina Kupczyńska), A.T.-K., R.W.-T, M.K. (Marek Kozirski), P.B., P.S., J.K., R.P., G.O., M.G. (Marcin Grabowski): none. A.K.-C.: received speaker fees from Bayer—outside the submitted work. I.G.-G.: received speaker fees from Bayer, Boehringer Ingelheim—outside the submitted work. L.D.-S.: received speaker fees from Bayer, Boehringer Ingelheim, and Pfizer—outside the submitted work. K.M.-S.: received speaker fees from Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Novartis, Servier—outside the submitted work. M.T.W.: received speaker fees from Bayer and Pfizer—outside the submitted work. A.T.-K.: received speaker fees from Boehringer-Ingelheim—outside the submitted work. M.K. (Marek Kozirski): received speaker fees from Bayer, Boehringer Ingelheim, Pfizer—outside the submitted work. G.O.: received speaker fees from Bayer, Boehringer Ingelheim, Pfizer—outside the submitted work.
References

1. Stoddard, M.F.; Singh, P.; Dawn, B.; Longaker, R.A. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. *Am. Heart J.* 2003, 145, 676–682. [CrossRef] [PubMed]

2. Gloekler, S.; Saw, J.; Koskinas, K.C.; Kleinecke, C.; Jung, W.; Nietlispach, F.; Meier, B. Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. *Int. J. Cardiol.* 2017, 249, 234–246. [CrossRef] [PubMed]

3. Reddy, V.Y.; Sievert, H.; Halperin, J.; Doshi, S.K.; Buchbinder, M.; Neuzil, P.; Huber, K.; Whisenant, B.; Kar, S.; Swarup, V.; et al. Percutaneous left atrial appendage closure vs. warfarin for atrial fibrillation: A randomized clinical trial. *JAMA* 2014, 312, 1988–1998. [CrossRef] [PubMed]

4. Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomstrom-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.A.; Diener, H.C.; Heidbuchel, H.; et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur. Heart J.* 2020, 42, 373–498. [CrossRef] [PubMed]

5. Kaplons-Cieslicka, A.; Budnik, M.; Gawalko, M.; Wojcik, M.; Blaszczzyk, R.; Uzielbo-Zyczkowska, B.; Kreszinski, P.; Starzyk, K.; Gorczycya, I.; Szymanska, A.; et al. The rationale and design of the LATTEE registry—The first multicenter project on the Scientific Platform of the “Club 30” of the Polish Cardiac Society. *Kardiol. Pol.* 2019, 77, 1078–1080. [CrossRef] [PubMed]

6. Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castella, M.; Diener, H.C.; Heidbuchel, H.; Hendriks, J.; et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europe. 2016, 18, 1609–1678.* [CrossRef] [PubMed]

7. Fatkin, D.; Kelly, R.P.; Feneley, M.P. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. *J. Am. Coll. Cardiol.* 1994, 23, 961–969. [CrossRef]

8. Noubiap, J.J.; Agbaedeng, T.A.; Ndoadoumgue, A.L.; Nyaga, U.F.; Kengne, A.P. Atrial thrombus detection on transoesophageal echocardiography in patients with atrial fibrillation undergoing cardioversion or catheter ablation: A pooled analysis of rates and predictors. *J. Cardiovasc. Electrophysiol.* 2021, 32, 2179–2188. [CrossRef] [PubMed]

9. Ruff, C.T.; Giugliano, R.P.; Braunwald, E.; Hoffman, E.B.; Ezekowitz, M.D.; Camm, A.J.; Weitz, J.I.; Lewis, B.S.; Parkhomenko, A.; et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. *Lancet* 2014, 383, 955–962. [CrossRef]

10. Silverio, A.; Di Maio, M.; Prota, C.; De Angelis, E.; Radano, I.; Citro, R.; Carrizzo, A.; Vecchione, C.; Capodanno, D.; et al. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: Systematic review and meta-analysis of 22 studies and 440 281 patients. *Eur. Heart J. Cardiovasc. Pharmacother.* 2021, 7, f20–f29. [CrossRef] [PubMed]

11. Gawalko, M.; Kaplons-Cieslicka, A.; Budnik, M.; Babiarz, A.; Bodys, A.; Ulinski, R.; Zochowski, M.; Peller, M.; et al. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion. *Pol. Arch. Intern. Med.* 2017, 127, 823–831. [CrossRef] [PubMed]

12. Haas, S.; Ten Cate, H.; Accetta, G.; Angchaisuksiri, P.; Bassand, J.P.; Corbalan, R.; Darius, H.; Fitzmaurice, D.A.; Goldhaber, S.Z.; et al. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. *PloS ONE* 2016, 11, e0164076. [CrossRef]

13. Reifel, J.A. Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials: Useful, but Also Misleading, Misused, and Overinterpreted. *Circulation* 2017, 135, 1475–1477. [CrossRef] [PubMed]

14. Noseworthy, P.A.; Yao, X.; Abraham, N.S.; Sangaralingham, L.R.; McBane, R.D.; Shah, N.D. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. *Chest* 2016, 150, 1302–1312. [CrossRef] [PubMed]

15. Lip, G.Y.; Larsen, T.B.; Skjøth, F.; Rasmussen, L.H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. *J. Am. Coll. Cardiol.* 2012, 60, 738–746. [CrossRef] [PubMed]

16. Steffel, J.; Collins, R.; Antz, M.; Cornu, P.; Destege, L.; Haeusler, K.G.; Oldgren, J.; Reinecke, H.; Roldan-Schilling, V.; Rowell, N.; et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *Europe. 2021, 23, 1612–1676.* [CrossRef] [PubMed]

17. Kaplons-Cieslicka, A.; Budnik, M.; Gawalko, M.; Peller, M.; Gorczycya, I.; Michalska, A.; Babiarz, A.; Bodys, A.; Ulinski, R.; Zochowski, M.; et al. Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus. *Heart* 2019, 105, 1310–1315. [CrossRef] [PubMed]

18. Budnik, M.; Gawalko, M.; Gorczycya, I.; Uzielbo-Zyczkowska, B.; Kreszinski, P.; Kochanowski, J.; Scislo, P.; Michalska, A.; Jelonk, O.; Starzyk, K.; et al. Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease. *Cardiol. J.* 2020, 29, 205–215. [CrossRef] [PubMed]

19. Kosmalska, K.; Rzyman, Z.; Miekus, P.; Gilis-Malinowska, N.; Nowak, R.; Fijalkowski, M. Usefulness of transesophageal echocardiography before cardioversion in atrial arrhythmias. *Cardiol. J.* 2021, 28, 101–109. [CrossRef] [PubMed]